|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
1,405.00 GBX |
+0.21% |
|
+3.58% | +4.34% |
January 31, 2025 at 07:33 am EST
To unlock the article, REGISTER!
© MT Newswires – 2025
|
GSK’s ViiV Healthcare Secures EU Approval for Vocabria Combination Therapy for HIV Treatment in Adolescents |
Jan. 31 |
MT |
|
GSK : Receives a Sell rating from JP Morgan |
Jan. 30 |
ZD |
|
GSK : UBS reaffirms its Neutral rating |
Jan. 30 |
ZD |
|
BioVersys launches IPO seeking to raise 80 million Swiss francs |
Jan. 29 |
RE |
|
BioVersys Seeks CHF75 Million from IPO on SIX Swiss Exchange |
Jan. 29 |
MT |
|
GSK Seeking Regulatory Approval for Long-Term Asthma Treatment in EU, Japan and China |
Jan. 28 |
MT |
|
GSK: depemokimab file advances in Europe and Asia |
Jan. 28 |
CF |
|
GSK applications for sinus disease treatment accepted for review |
Jan. 28 |
AN |
|
GSK’s Depemokimab Submissions Accepted for EU Review for Asthma, Rhinosinusitis |
Jan. 28 |
MT |
|
GSK plc Announces Acceptancy of Depemokimab Applications for Review in China and Japan for Asthma with Type 2 Inflammation and CRSwNP |
Jan. 28 |
CI |
|
European Equities Close Mixed in Monday Trading; Tesla Sues EC Over China Duties |
Jan. 27 |
MT |
|
FTSE 100 steady but Deepseek sparks US tech rout |
Jan. 27 |
AN |
|
Global markets live: Nvidia, AT&T, Biogen, Tesla, Nokia… |
Jan. 27 |
 |
|
GSK Partners With Oxford University to Advance Cancer Vaccine Research |
Jan. 27 |
MT |
|
GSK’s Application for Prefilled Syringe of Shingles Vaccine Accepted for European Review |
Jan. 27 |
MT |
|
Gsk plc Announces the European Medicines Agency Accepts for Review the Regulatory Application of A Prefilled Syringe Presentation of Shingrix |
Jan. 27 |
CI |
|
GSK: collaboration with Oxford on cancer vaccine |
Jan. 27 |
CF |
|
GSK: EMA examines new Shingrix presentation |
Jan. 27 |
CF |
|
GSK and University of Oxford researchers to create cancer vaccine |
Jan. 27 |
AN |
|
GSK shingles treatment application accepted for review in Europe |
Jan. 27 |
AN |
|
Diageo rules out Guinness sale; Dr Martens backs view |
Jan. 27 |
AN |
|
Global markets live: Charles Schwab, Apple, Tesla, Enel, GSK… |
Jan. 21 |
|
|
Swiss biopharma firm BioVersys plans IPO in first quarter |
Jan. 21 |
RE |
|
GSK’s Jemperli Gets Expanded Approval From European Commission |
Jan. 21 |
MT |
|
Biopharmaceutical Company BioVersys Plans Swiss Bourse IPO in Q1 |
Jan. 21 |
MT |
GSK: Dynamic Chart
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
More about the company
Buy
Last Close Price
14.05GBP
Average target price
17.94GBP
Spread / Average Target
+27.68%
Consensus
Quarterly revenue – Rate of surprise
link